AQR Capital Management LLC Purchases 30,635 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

AQR Capital Management LLC raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 26.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 144,693 shares of the biotechnology company's stock after acquiring an additional 30,635 shares during the quarter. AQR Capital Management LLC owned about 0.23% of Blueprint Medicines worth $12,620,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Torray Investment Partners LLC lifted its stake in Blueprint Medicines by 1.1% in the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock valued at $1,439,000 after acquiring an additional 186 shares during the last quarter. Franklin Resources Inc. lifted its stake in Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after acquiring an additional 265 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Blueprint Medicines by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock valued at $580,000 after acquiring an additional 283 shares during the last quarter. Pitcairn Co. lifted its stake in Blueprint Medicines by 2.8% in the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock valued at $925,000 after acquiring an additional 293 shares during the last quarter. Finally, Hillsdale Investment Management Inc. lifted its stake in Blueprint Medicines by 0.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock valued at $4,433,000 after acquiring an additional 310 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BPMC. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an "outperform" rating for the company. Morgan Stanley assumed coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price objective for the company. JMP Securities restated a "market outperform" rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Scotiabank assumed coverage on shares of Blueprint Medicines in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 price objective for the company. Finally, StockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $126.56.

Blueprint Medicines Stock Performance

NASDAQ:BPMC traded down $1.02 during trading hours on Friday, hitting $97.74. 621,844 shares of the company traded hands, compared to its average volume of 780,742. The stock has a market capitalization of $6.31 billion, a price-to-earnings ratio of -90.50 and a beta of 0.83. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The firm has a 50-day moving average of $88.49 and a 200 day moving average of $93.88. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The business had revenue of $149.41 million during the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the firm earned $1.40 EPS. On average, analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares of the company's stock, valued at $6,581,655.32. The trade was a 3.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. This trade represents a 14.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,503 shares of company stock valued at $1,027,931 in the last 90 days. 4.21% of the stock is currently owned by company insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.